Global RNA Therapy Clinical Trials Market to Grow with a CAGR of 5.06% through 2028
The rising growing prevalence of genetic diseases are expected to drive
the Global RNA Therapy Clinical Trials Market in the forecast period 2024-2028.
According to TechSci Research report, “Global
RNA Therapy Clinical Trials Market –Industry Size, Share, Trends, Competition,
Opportunity and Forecast, 2018-2028”, the Global
RNA Therapy Clinical Trials Market stood at USD 2.62 billion in 2022 and is
anticipated to project robust growth in the forecast period with a CAGR of 5.06%
through 2028. This phenomenon can be attributed to the cooperative efforts and
alliances formed by prominent businesses, which employ a varied strategy to
combine the specialized knowledge of each company, thereby enhancing their
market presence. Additionally, the recent advancements and developments of niche
technologies are expected to propell the growth of Global RNA Therapy Clinical
Trials Market by launches of new therapies for different applications, rising
government initiatives, etc are expected to rise the growth of Global RNA
Therapy Clinical Trials Market.
RNA Therapy Clinical Trials hold significant
promise across a spectrum of medical applications, offering innovative
approaches to address a wide range of diseases and conditions. The versatility
and precision of RNA-based therapies have sparked growing interest and research
efforts in various therapeutic areas within the field of clinical trials. RNA
Therapy Clinical Trials are revolutionizing cancer treatment by targeting
specific genetic mutations or overexpressed genes that drive tumor growth. mRNA
vaccines and siRNA therapies are being explored to inhibit the expression of
oncogenes, while immunomodulatory RNA therapies aim to enhance the body's
immune response against cancer cells. These therapies have the potential to be
more selective, less toxic, and more adaptable to tumor heterogeneity compared
to traditional chemotherapy. RNA therapies hold promise for treating genetic
disorders caused by single gene mutations, such as cystic fibrosis, muscular
dystrophy, and Huntington's disease. ASOs can be designed to correct abnormal
gene splicing patterns or promote the degradation of disease-causing RNA
molecules, offering a potential avenue to address the root causes of these
conditions.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on "Global RNA Therapy Clinical Trials Market.”
RNA Therapy Clinical Trials are exploring treatments for
neurodegenerative disorders like Alzheimer's, Parkinson's, and amyotrophic
lateral sclerosis (ALS). ASOs and other RNA molecules are designed to target
genes associated with disease progression, potentially slowing down or halting
degeneration and providing neuroprotection. RNA therapies have garnered
attention due to the success of mRNA vaccines against infectious diseases like
COVID-19. Beyond vaccines, RNA Therapy Clinical Trials are investigating
antiviral siRNA therapies that inhibit viral replication, offering potential
treatments for HIV, hepatitis B, and respiratory viruses. Many rare diseases
lack effective treatments.
RNA Therapy Clinical Trials are exploring
personalized approaches to target specific genetic mutations underlying these
conditions. This includes disorders like Duchenne muscular dystrophy,
phenylketonuria (PKU), and rare genetic metabolic disorders. RNA therapies are
being investigated as potential treatments for cardiovascular diseases such as
heart failure and hypercholesterolemia. mRNA therapies can stimulate the
production of beneficial proteins, while siRNA therapies can silence genes
associated with cholesterol metabolism. RNA-based therapies offer the
possibility of modulating immune responses in autoimmune diseases like
rheumatoid arthritis, multiple sclerosis, and lupus. By targeting
immune-related genes or inflammatory pathways, these therapies aim to restore
immune balance and mitigate disease symptoms.
However, the preference for appropriate technology,
competitive market landscape and growing concerns for human health are expected
to slow down the growth of the Global RNA Therapy Clinical Trials Market in the
coming years.
The Global RNA Therapy Clinical Trials Market segmentation
is based on Modality, Phase, Therapeutic Areas, Company, and Region.
Some of the major companies operating in the Global
RNA Therapy Clinical Trials Market include:
- IQVIA
Inc
- ICON
Plc
- Laboratory
Corporation of America Holdings
- Charles
River Laboratories International, Inc.
- PAREXEL
International Corp.
- Syneos
Health
- Medpace
Holdings, Inc.
- Novotech
Inc
- Veristat,
LLC.
- Veristat,
LLC.
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“North America is expected to dominate in the RNA
Therapy Clinical Trials Market due to the presence of many pharmaceutical and
biotechnology companies in the region, as well as significant government
funding for research and development in the life sciences. Similarly, these
technologies are critical for developing new treatments and therapies along
with the growing prevalence of chronic diseases such as cancer is expected to
create lucrative growth in the market during the forecast period. Also, growing
government funding for healthcare infrastructure and a large and rapidly expanding
population is expected to drive the growth of the market during the forecast
period" said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
RNA Therapy Clinical Trials Market - Global Industry Size, Share,
Trends, Competition, Opportunity, and Forecast, 2018-2028, Segmented By Product (Small Molecule API, Small Molecule Drug Product),
By Stage Type (Preclinical, Clinical, Commercial), By Customer Type
(Pharmaceutical, Biotechnology), By Therapeutic Area (Cardiovascular disease,
Oncology, Respiratory disorders, Neurology, Metabolic disorders, Infectious
disease, Others), By Region, Competition, Forecast and Opportunities, 2028 has evaluated the future growth potential of Global
RNA Therapy Clinical Trials Market and provides statistics & information on
market size, structure, and future market growth. The report intends to provide
innovative market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global RNA
Therapy Clinical Trials Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New York
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com